# Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

> clinical trial · VERIFIED · 2026-08-14

Status: RECRUITING · Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Condition: Resectable Gastric/Gastroesophageal Junction Adenocarcinoma

- Company: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07643623

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.